Literature DB >> 24111860

Incretin-based therapies: facing the realities of benefits versus side effects.

Harold E Lebovitz1.   

Abstract

Mesh:

Substances:

Year:  2013        PMID: 24111860      PMCID: PMC3817865          DOI: 10.1089/dia.2013.0274

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


× No keyword cloud information.
  40 in total

1.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

2.  Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?

Authors:  Deborah Cohen
Journal:  BMJ       Date:  2013-06-07

3.  Glucagonlike Peptide 1-based drugs and pancreatitis: clarity at last, but what about pancreatic cancer?

Authors:  Belinda Gier; Peter C Butler
Journal:  JAMA Intern Med       Date:  2013-04-08       Impact factor: 21.873

Review 4.  Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.

Authors:  Andre Scheen
Journal:  Expert Opin Drug Saf       Date:  2013-04-27       Impact factor: 4.250

5.  Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.

Authors:  Rajesh Garg; William Chen; Merri Pendergrass
Journal:  Diabetes Care       Date:  2010-08-03       Impact factor: 17.152

6.  Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.

Authors:  Sonal Singh; Hsien-Yen Chang; Thomas M Richards; Jonathan P Weiner; Jeanne M Clark; Jodi B Segal
Journal:  JAMA Intern Med       Date:  2013-04-08       Impact factor: 21.873

7.  Exenatide-induced acute pancreatitis.

Authors:  Walaa A Ayoub; Ashok A Kumar; Hossam S Naguib; Harris C Taylor
Journal:  Endocr Pract       Date:  2010 Jan-Feb       Impact factor: 3.443

Review 8.  Pancreatitis: a potential complication of liraglutide?

Authors:  Andrea S Franks; Phillip H Lee; Christa M George
Journal:  Ann Pharmacother       Date:  2012-11-07       Impact factor: 3.154

9.  The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.

Authors:  Niels C B Nyborg; Anne-Marie Mølck; Lars W Madsen; Lotte Bjerre Knudsen
Journal:  Diabetes       Date:  2012-02-14       Impact factor: 9.461

10.  Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study.

Authors:  Rebecca A Noel; Daniel K Braun; Ruth E Patterson; Gary L Bloomgren
Journal:  Diabetes Care       Date:  2009-02-10       Impact factor: 17.152

View more
  1 in total

1.  Polysaccharide IV from Lycium barbarum L. Improves Lipid Profiles of Gestational Diabetes Mellitus of Pregnancy by Upregulating ABCA1 and Downregulating Sterol Regulatory Element-Binding Transcription 1 via miR-33.

Authors:  Shuli Yang; Lihui Si; Limei Fan; Wenwen Jian; Huilin Pei; Ruixin Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2018-02-23       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.